Latest acute coronary syndromes Stories
Sub-analyses Investigate the Effects of alogliptin on Cardiovascular Mortality Rates and Hospitalization for Heart Failure in Type 2 Diabetes Patients with Recent Acute Coronary Syndrome
Additional Findings from RADAR Trial Published in Journal of Invasive Cardiology BASKING RIDGE, N.J., Jan. 29, 2014 /PRNewswire/ -- Regado Biosciences, Inc.
Older heart patients present unique challenges for determining the optimal dosages of medications, so a new study from researchers at Duke Medicine offers some rare clarity about the use of drugs that are used to treat patients with heart attacks.
INDIANAPOLIS and TOKYO, Aug.
Two relatively simple methods, an ultrasound investigation and a blood test to measure the level of a substance known as BNP, can predict survival and future heart failure following acute coronary syndromes.
Patients with acute coronary syndromes initially treated with the anticoagulant fondaparinux who underwent a coronary procedure (such as balloon angioplasty) and received a lower dose of the anticoagulant heparin during the procedure did not have a reduced rate of major bleeding and vascular access site complications.
The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke.
ATLANTA, March 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA(TM)/BRILIQUE(TM)) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.(1) These...
- A political dynamiter.